Voyager reports VY1706 Alzheimer’s therapy data

• Voyager Therapeutics reported six-month GLP toxicology results for its Alzheimer’s gene therapy candidate VY1706.
• A single dose reduced MAPT mRNA and tau protein levels by up to 75% in key brain regions.
• Voyager said FDA clearance allows the company to begin a clinical trial in early Alzheimer’s disease patients.

Voyager Therapeutics (NASDAQ:VYGR) reported six-month toxicology results for VY1706, its investigational tau-targeted gene therapy for Alzheimer’s disease, showing sustained reductions in MAPT mRNA and tau protein levels in non-human primates.

The results were presented at the AAIC 2026 conference in London and follow the U.S. Food and Drug Administration’s clearance of Voyager’s Investigational New Drug application for VY1706 in June.

In the study, a single intravenous dose of VY1706 produced reductions of up to 75% in MAPT mRNA and tau protein across key Alzheimer’s-related brain regions over six months, with no adverse clinical pathology or histopathological findings reported.

Voyager said VY1706 was well tolerated at the highest tested dose of 5E13 vg/kg.

VY1706 is designed to target tau, a protein associated with Alzheimer’s disease progression, using Voyager’s gene therapy platform and ALPL-mediated blood-brain barrier transport technology.

Voyager plans to begin dosing adults with early Alzheimer’s disease in a clinical trial during the second half of 2026, with the company continuing to evaluate the potential of its gene therapy platform.